Other

University System of Maryland

Flavocure Biotech, Inc.

Vilotos Pharmaceuticals, Inc.

Educational & Scientific LLC

Henry Lowe

Ngeh J Toyang

Joseph Bryant

Joseph L Bryant

An embodiment of the invention provides a-based flavonoid pharmaceutical composition including any one or more selected, from among the group of Apigenin, Cannflavin. A. Cannflavin B, Cannflavin C, Chrysoeriol, Cosmosiin, Flavocannabiside, Kaempferol, Luteolin, Myricetin, Orientin, Isoorientin (Homoorientin), Quercetin (+)-Taxifolin, Vitexin, and Isovitexin, or their synthases, for the prevention and treatment of certain cancers that can be treated by therapeutically targeting oncogenic factors including kinases, sirtuins, bromodomains, matrix metalloproteinases and BCL-2. Some of the cancers that can be treated by use offlavonoids based on the inhibition of these therapeutic targets include brain, breast, colon, renal, liver, lung, pancreatic, prostate, leukemia, melanoma as well as any other cancers that overexpress the oncogenic factors inhibited by theflavonoids identified herein.

Therapeutic agents containing cannabis flavonoid derivatives targeting kinases, sirtuins and oncogenic agents for the treatment of cancers

A cannabinoid-based pharmaceutical composition for the prevention and treatment of pathogenic viruses (particularly those causing hepatic related conditions such as hepatitis B and C), and most particularly for hepatitis C virus (HCV) infection, having a cannabidiol structure or a pharmaceutically acceptable salt thereof. A method for the prevention and treatment of pathogenic viruses (particularly those causing viral hepatic related conditions such as hepatitis B and C), and most particularly for HCV is also disclosed.

Treating hepatitis C with cannabidiol

A pharmaceutical composition for the prevention and treatment of cancer with specific flavanoid-based compounds selected from among the groups of Flavone, Flavanone and Flavanol, a method for the prevention and treatment of cancer and inflammation using the specific flavonoid-based pharmaceutical compositions, a method for isolating the flavonoid-based pharmaceutical compositions from raw plant material, and a method for synthesizing said specific flavonoid-based pharmaceutical compositions.

Agent containing flavonoid derivatives for treating cancer and inflammation

An embodiment of the invention provides a cannabis-based flavonoid pharmaceutical composition including any one or more selected, from among the group of Apigenin, Cannflavin. A. Cannflavin B, Cannflavin C, Chrysoeriol, Cosmosiin, Flavocannabiside, Kaempferol, Luteolin, Myricetin, Orientin, Isoorientin (Homoorientin), Quercetin (+)-Taxifolin, Vitexin, and Isovitexin, or their synthases, for the prevention and treatment of certain cancers that can be treated by therapeutically targeting oncogenic factors including kinases, sirtuins, bromodomains, matrix metalloproteinases and BCL-2. Some of the cancers that can be treated by use of cannabis flavonoids based on the inhibition of these therapeutic targets include brain, breast, colon, renal, liver, lung, pancreatic, prostate, leukemia, melanoma as well as any other cancers that overexpress the oncogenic factors inhibited by the cannabis flavonoids identified herein.

A therapeutic phenolic extract derived from plant biomass, and more specifically the indigenous Jamaican plantL. (Zygophyllaceae), for use in regressing or controlling HIV-1 replication in infected patients, and to help prevent sexual transmission of HIV-1, as well as the method for inhibiting HIV-1 by administering a pharmaceutically-acceptable amount of the crude extract to prevent HIV-viral replication without causing excessive damage to normal cells.

[object Object]

A method of treating prostate cancer by administering a pharmaceutically-acceptable amount of a crude extract of the indigenous Jamaican plant Ball Moss () comprising one or more cycloartane isolates, and the isolates used in the method for eliciting thereby a kinase inhibitory response of prostate cancer cells by selectively inhibiting MRCK&#x3b1; kinase and angiogenesis of (growth of new blood vessels) to reduce the viability of prostate cancer cells. The method and compounds holds promise as a chemopreventive agent, without causing excessive damage to normal cells.

Methods for inhibiting prostate cancer by kinases and angiogenesis inhibitory mechanisms of ball moss extract

Synthetic dicinnamate compounds and their analogs are disclosed that exhibit anti-tumor activity and/or an anti-inflammatory activity, and have beneficial activity principally in destroying cancer cells. Furthermore, methods for the extraction of the extracts are disclosed.

Anti-tumor and anti-inflammatory dicinnamoyl-glycerol esters and their analogues

Extracts from an indigenous Jamaican plant that exhibit an anti-tumor activity and/or an anti-inflammatory activity and, more particularly, an extract of Jamaican Ball Moss () that has a therapeutic pharmacological activity, in particular an anti-cancerous activity by inducing tumorous cell death by apoptosis, and active compounds isolated thereof are described. Furthermore, methods for the extraction of the extracts are disclosed. Also, a pharmaceutical composition or product for the treatment of cancer which includes an effective amount of the described extract or an active compound thereof, a therapeutic compound and optionally a pharmaceutical acceptable carrier are described.

Growing community of inventors

West Indies, Jamaica

Henry Lowe